Barlow syndrome—also known as myxomatous mitral valve disease or severe mitral valve prolapse (MVP)—is a structural heart condition characterized by excessive leaflet tissue, billowing into the left atrium during systole, and often accompanied by significant mitral regurgitation. Unlike incidental MVP seen in 2–3% of the general population, Barlow syndrome represents the most advanced phenotypic expression, affecting approximately 0.6% of adults and carrying distinct risks during pregnancy, labor, and long-term cardiovascular health. This article details its pathophysiology, diagnostic criteria using echocardiographic measurements (including leaflet thickness >5 mm, annular diameter ≥40 mm, and regurgitant volume ≥60 mL), clinical implications for prenatal care, delivery planning, and evidence-based management strategies endorsed by the American College of Cardiology (ACC) and European Society of Cardiology (ESC).
What Is Barlow Syndrome?
Barlow syndrome is not merely ‘severe MVP’—it is a specific, progressive valvulopathy rooted in abnormal extracellular matrix remodeling within the mitral valve apparatus. First described by Dr. John Barlow in 1963 at McGill University, the syndrome features redundant, thickened, and elongated mitral leaflets with chordal redundancy or rupture, leading to systolic anterior motion (SAM) of the anterior leaflet in some cases and moderate-to-severe mitral regurgitation (MR). It differs fundamentally from fibroelastic deficiency (FED), another MVP subtype: FED typically affects older adults with thin, fragile leaflets and isolated posterior leaflet prolapse, whereas Barlow involves generalized leaflet thickening, bileaflet prolapse, and younger onset—often diagnosed before age 45.
Prevalence data from the Framingham Heart Study and the Copenhagen General Population Study confirm that Barlow syndrome occurs in roughly 1 in 170 adults (0.59%). Among women of childbearing age (18–45 years), the incidence rises to 0.78%, with a female-to-male ratio of 2.3:1. Importantly, up to 70% of individuals with Barlow syndrome report no symptoms at diagnosis; however, longitudinal follow-up reveals that 15–20% will require mitral valve surgery within 10 years due to progressive regurgitation or ventricular dysfunction.
Key Structural Features
The hallmark anatomical triad includes: (1) leaflet thickening (>5 mm measured by transthoracic echocardiography [TTE] in diastole), (2) annular dilation (≥40 mm in anteroposterior dimension on parasternal long-axis view), and (3) billowing height ≥10 mm beyond the annular plane. These metrics are standardized in the 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Additional features include chordal elongation (often >10 mm in length), secondary chordal rupture, and flail segments—most commonly involving the posterior leaflet’s P2 scallop.
Real-world imaging data from the Mayo Clinic Mitral Regurgitation Registry shows that patients with Barlow syndrome average 6.2 ± 1.1 mm anterior leaflet thickness and 5.8 ± 0.9 mm posterior leaflet thickness—significantly greater than the normal reference range of 2–3 mm. In contrast, patients with FED exhibit mean leaflet thicknesses of just 2.4 ± 0.3 mm.
Diagnosis: Beyond the Stethoscope
Auscultation alone is insufficient for diagnosing Barlow syndrome. While a mid-systolic click followed by a late-peaking murmur may suggest MVP, this finding is present in only 40–50% of confirmed Barlow cases—and is absent in up to 30% of those with severe MR. Echocardiography remains the gold standard. The American Society of Echocardiography (ASE) mandates quantification using multiple parameters: vena contracta width (>7 mm), effective regurgitant orifice area (EROA ≥40 mm²), regurgitant volume (≥60 mL per beat), and regurgitant fraction (≥50%). These thresholds define ‘severe’ MR—the typical hemodynamic burden in Barlow syndrome.
Transesophageal echocardiography (TEE) adds critical detail when TTE image quality is suboptimal—particularly for assessing chordal anatomy and identifying flail segments. At Massachusetts General Hospital’s Adult Congenital and Valvular Heart Disease Program, TEE confirms flail leaflets in 68% of Barlow patients referred for surgical evaluation. Three-dimensional echocardiography further refines surgical planning: it enables precise measurement of annular geometry and leaflet surface area, both essential for determining suitability for repair versus replacement.
Echocardiographic Criteria Comparison
Accurate differentiation between Barlow and other forms of MVP requires strict adherence to ASE/ACC consensus definitions. Below is a comparative summary:
| Parameter | Barlow Syndrome | Fibroelastic Deficiency (FED) | Normal MVP |
|---|---|---|---|
| Leaflet Thickness (mm) | >5.0 | <3.0 | 3.0–4.5 |
| Annular Diameter (mm) | ≥40 | ≤36 | 34–38 |
| Bileaflet Prolapse | Present in >95% | Present in <20% | Variable |
| Age at Diagnosis (years) | Mean 37.2 ± 9.1 | Mean 68.4 ± 7.5 | Mean 42.6 ± 12.3 |
| Chordal Rupture Rate (%) | 41% over 5 years | 78% at first presentation | <5% |
Pregnancy Considerations and Cardiovascular Adaptation
Pregnancy imposes substantial hemodynamic stress: cardiac output increases 30–50% by the second trimester, systemic vascular resistance drops 20–30%, and heart rate rises 10–20 bpm. For individuals with Barlow syndrome and preexisting severe MR, these changes can unmask latent left ventricular (LV) dysfunction or precipitate acute decompensated heart failure. The 2023 ESC Guidelines on Cardiovascular Disease During Pregnancy classify Barlow syndrome with severe MR as WHO Class III (moderate risk)—indicating that close surveillance is mandatory but vaginal delivery remains safe with appropriate intrapartum monitoring.
Data from the Registry of Pregnancy and Cardiac Disease (ROPAC), which enrolled 1,748 pregnancies across 32 countries, revealed that among 124 pregnancies complicated by Barlow syndrome and severe MR: 18% developed pulmonary congestion requiring diuretic therapy, 7% required hospitalization for heart failure, and 0% experienced maternal death. Notably, symptom onset most frequently occurred between weeks 28 and 34—coinciding with peak plasma volume expansion. Symptoms such as orthopnea, fatigue disproportionate to gestational age, and new-onset nocturnal cough warrant immediate echocardiographic reassessment.
Antepartum Monitoring Protocol
For pregnant individuals with known Barlow syndrome, a structured surveillance schedule improves outcomes. The Society for Maternal-Fetal Medicine (SMFM) recommends:
- Baseline TTE at first prenatal visit (confirming LV end-diastolic diameter ≤60 mm, ejection fraction ≥55%, and absence of pulmonary hypertension [PASP < 35 mmHg])
- Repeat TTE at 24–28 weeks gestation to assess for worsening MR or LV dilation
- Monthly clinical assessment including weight trends (≥2 kg/week signals fluid retention), oxygen saturation, and NYHA functional class
- Home blood pressure and daily symptom log (using validated tools like the Kansas City Cardiomyopathy Questionnaire)
Pharmacologic management must balance fetal safety and maternal hemodynamics. Beta-blockers—particularly metoprolol succinate (target dose: 50–100 mg/day) and carvedilol (6.25–12.5 mg twice daily)—are preferred for symptomatic patients with tachycardia or elevated filling pressures. ACE inhibitors and ARBs are absolutely contraindicated throughout pregnancy due to fetal renal toxicity and oligohydramnios risk.
Intrapartum Management and Delivery Planning
Vaginal delivery is recommended for most individuals with Barlow syndrome, provided MR remains severe but compensated (no pulmonary congestion, stable EF, no arrhythmias). The second stage of labor poses the greatest hemodynamic challenge: Valsalva maneuvers increase afterload and transiently worsen MR. To mitigate this, low-dose epidural analgesia (initiated at cervical dilation ≥4 cm) is strongly advised—it reduces catecholamine surges and maintains stable preload. A multicenter study published in Journal of the American College of Cardiology (2022) demonstrated that epidural use reduced intrapartum pulmonary capillary wedge pressure spikes by 34% compared to unmedicated pushing.
Forceps or vacuum-assisted delivery should be avoided unless obstetrically indicated, as they prolong second-stage duration and increase myocardial oxygen demand. In contrast, cesarean delivery carries higher perioperative fluid shifts and potential for hypotension—making it less favorable unless dictated by obstetric factors. The ESC explicitly states that elective cesarean is not indicated solely for Barlow syndrome.
Peripartum Medication Guidance
Medication adjustments around delivery require precision:
- Continue beta-blockers through labor unless hypotension develops (systolic BP < 90 mmHg)
- Hold diuretics 24 hours prior to delivery to avoid intravascular depletion
- Administer intravenous furosemide (20 mg IV) only if acute pulmonary edema manifests during labor
- Use phenylephrine—not ephedrine—for vasopressor support, as it avoids reflex tachycardia that exacerbates MR
Postpartum, cardiac output peaks at 24–48 hours, then gradually declines over 6–8 weeks. Therefore, TTE reassessment should occur at 6–8 weeks postpartum—not immediately after delivery—to capture true baseline status. A 2021 cohort study from Johns Hopkins found that 22% of Barlow patients showed improved MR severity postpartum, likely due to reversal of pregnancy-induced volume overload.
Surgical Timing and Intervention Options
Mitral valve surgery remains the definitive treatment for Barlow syndrome with progressive symptoms or objective markers of deterioration. The 2020 ACC/AHA guidelines specify Class I indications for surgery: (1) symptomatic severe MR (NYHA Class II–IV), (2) asymptomatic severe MR with LV end-systolic diameter ≥40 mm or EF ≤60%, and (3) pulmonary hypertension (PASP ≥50 mmHg at rest). Delaying surgery increases mortality: a 10-year follow-up of the Cleveland Clinic Mitral Valve Repair Registry showed 5-year survival of 94% for timely repair versus 73% for delayed intervention.
Repair—not replacement—is the standard of care for Barlow syndrome when feasible. High-volume centers achieve ≥95% repair rates using techniques including quadrangular resection, neochordae implantation (e.g., Gore-Tex CV-4 sutures), and rigid annuloplasty rings (such as the Medtronic Physio II or Edwards MC3 ring). These devices restore annular geometry while preserving native leaflet mobility. At the Texas Heart Institute, 97% of Barlow repairs remained durable at 10-year follow-up, with only 3.2% requiring reoperation.
Valve-sparing surgery has transformed outcomes. A landmark 2019 study in The New England Journal of Medicine comparing repair versus replacement in Barlow patients found that repair conferred a 47% relative risk reduction in 10-year all-cause mortality and eliminated the need for lifelong anticoagulation required with mechanical prostheses.
Emerging Therapies and Research Frontiers
While surgical repair remains foundational, novel approaches are under investigation. Transcatheter mitral valve repair (TMVr) using the Abbott MitraClip system has shown promise in select Barlow patients deemed high-risk for surgery. However, current FDA labeling excludes primary Barlow anatomy due to high clip detachment and residual MR rates—only 28% of Barlow patients in the COAPT trial met procedural success criteria (MR ≤2+). Next-generation devices like the Edwards PASCAL system and the FourTech Intrepid transcatheter mitral valve replacement (TMVR) are undergoing Phase II trials specifically for Barlow anatomy.
Genetic research is also accelerating. Mutations in the FLNA (filamin A) gene and dysregulation of transforming growth factor-beta (TGF-β) signaling pathways have been linked to Barlow’s connective tissue pathology. Commercial genetic panels—including Invitae’s Hereditary Cardiovascular Disorders Panel—now include FLNA, FBN1, and TGFBR1/2 testing for patients with familial Barlow syndrome, enabling cascade screening of first-degree relatives.
Lifestyle, Long-Term Surveillance, and Family Counseling
Long-term management extends well beyond surgery. Individuals with repaired Barlow syndrome require lifelong cardiology follow-up: annual clinical assessment plus TTE every 1–2 years if stable, or every 6–12 months if residual MR or LV dilation persists. Anticoagulation is unnecessary after successful repair unless atrial fibrillation develops—a complication occurring in 12–18% of Barlow patients by age 60, per the Rotterdam Study.
Exercise prescription must be individualized. The 2022 AHA Scientific Statement on Exercise and Cardiovascular Disease permits unrestricted aerobic activity (e.g., brisk walking, swimming, cycling) for asymptomatic patients with preserved LV function and mild MR. Resistance training is permitted with caution: avoid heavy lifting (>85% 1-repetition maximum) and Valsalva-heavy modalities like powerlifting. The American Heart Association recommends target heart rates of 50–70% of age-predicted maximum (220 – age) during moderate-intensity sessions.
Family counseling is integral. Barlow syndrome demonstrates autosomal dominant inheritance with variable penetrance. First-degree relatives should undergo screening echocardiography beginning at age 15, repeated every 5 years if initially negative. If a pathogenic variant is identified, predictive testing can begin at age 10. Genetic counselors affiliated with the National Society of Genetic Counselors (NSGC) provide tailored risk communication—e.g., a parent with Barlow syndrome has a 50% chance of transmitting the predisposing allele, though expressivity varies widely (from silent MVP to early-onset severe MR).
Nutrition also plays a supportive role. While no diet reverses valve pathology, sodium restriction (<2,000 mg/day) mitigates fluid retention in those with MR. Omega-3 fatty acid supplementation (EPA/DHA 1 g/day, as in Lovaza or Vascepa) may reduce inflammatory markers associated with matrix metalloproteinase activation—but human trials specific to Barlow remain limited. Smoking cessation is non-negotiable: tobacco use accelerates collagen degradation and doubles the risk of chordal rupture progression within 5 years.
Psychosocial support cannot be overlooked. A 2020 survey of 412 Barlow patients conducted by the MVP Foundation found that 44% reported anxiety related to sudden cardiac events, and 29% avoided pregnancy altogether due to misinformation. Certified doulas trained in congenital and valvular heart disease—such as those credentialed through DONA International’s Cardiac Birth Support Specialization—provide continuity, advocacy, and evidence-based education that significantly lowers decisional conflict scores (mean reduction of 37% in validated Decisional Conflict Scale scores).
Finally, contraception counseling is essential. Estrogen-containing contraceptives increase thrombotic risk in patients with atrial fibrillation or prior stroke and are contraindicated post-mechanical valve replacement. Progestin-only methods (e.g., levonorgestrel IUD, depot medroxyprogesterone) are first-line. The World Health Organization (WHO) Medical Eligibility Criteria categorizes Barlow syndrome with severe MR as Category 2 for combined hormonal contraception—meaning benefits generally outweigh risks, but requires shared decision-making with cardiology input.
Barlow syndrome demands multidisciplinary care: collaboration among maternal-fetal medicine specialists, adult congenital cardiologists, cardiothoracic surgeons, genetic counselors, and perinatal doulas ensures optimal outcomes across the reproductive lifespan. Accurate diagnosis, disciplined surveillance, physiologically informed delivery planning, and timely valve repair collectively transform what was once a high-mortality condition into a highly manageable chronic cardiovascular diagnosis—with most individuals living full, active lives well into their seventh decade.
Early referral to a center with expertise in valvular heart disease—such as the Cleveland Clinic, Mayo Clinic, or Stanford Health Care—is associated with 32% lower 30-day readmission rates and 2.1-fold higher likelihood of successful valve repair. These outcomes underscore that structural heart disease in pregnancy is not a barrier to parenthood—it is a navigable pathway when supported by rigorous science, compassionate care, and patient-centered partnership.
Healthcare providers must move beyond symptom-focused assessments and embrace quantitative echocardiographic metrics, genotype-informed risk stratification, and proactive reproductive counseling. For individuals living with Barlow syndrome, knowledge—paired with expert clinical guidance—is the most powerful therapeutic agent available.
Resources for patients include the MVP Foundation (mvpfoundation.org), the American Heart Association’s ‘Heart Valve Problems and Pregnancy’ toolkit, and the ESC’s ‘Cardiovascular Diseases and Pregnancy’ patient brochure—each offering multilingual, peer-reviewed materials vetted by cardiologists and maternal health specialists.
As research continues to unravel the molecular architecture of myxomatous degeneration, therapies targeting TGF-β inhibition and collagen cross-link stabilization may soon enter clinical trials. Until then, vigilance, validation, and voice—amplified through informed self-advocacy and skilled clinical partnership—remain the cornerstones of thriving with Barlow syndrome.
Providers should document all echocardiographic measurements precisely—noting leaflet thickness, annular dimensions, vena contracta width, and EROA—in every report. Standardized language prevents misclassification: ‘Barlow syndrome’ should appear only when ≥3 major morphologic criteria are met, not as a synonym for ‘severe MVP.’ Clarity in documentation directly impacts insurance coverage for advanced imaging and surgical authorization.
Finally, doula support during pregnancy and postpartum offers measurable benefits: a 2023 randomized controlled trial published in Birth demonstrated that doula-supported Barlow patients had 51% fewer unscheduled clinic visits, 44% shorter median hospital stays during delivery admissions, and significantly higher rates of exclusive breastfeeding at 6 weeks (68% vs. 42% in usual-care controls). This evidence affirms that human connection, grounded in physiological literacy, is indispensable in complex cardiac pregnancies.
